The U.S. FDA approved an expanded 26-week efficacy claim for Zimmer Biomet Holdings Inc.'s Gel-One Cross-linked Hyaluronate for the treatment of knee pain associated with osteoarthritis.
Discover more about S&P Global’s offerings
US FDA approves expanded efficacy claim for Zimmer's knee pain drug
Essential IR Insights Newsletter Fall - 2023
A Corporation Clearly Pinpoints Activist Investor Activity
Insight Weekly: Bank mergers of equals return; energy tops S&P 500; green bond sales to rise
Insight Weekly: US companies boost liquidity; auto insurers hike rates; office sector risk rises
The U.S. FDA approved an expanded 26-week efficacy claim for Zimmer Biomet Holdings Inc.'s Gel-One Cross-linked Hyaluronate for the treatment of knee pain associated with osteoarthritis.